Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)

v3.22.1
Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 02, 2020
USD ($)
Feb. 25, 2019
USD ($)
agreement
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights     $ 5,000 $ 13,500  
Long-term royalty and commercial payment receivables     69,075   $ 69,075
Contingent consideration under RPAs and CPPAs     3,075   8,075
Impairment of long-term royalty receivable     0   $ 0
Bioasis | Royalty Purchase Agreement          
Agreements          
Percentage of option to purchase royalty right on future license agreements   1.00%      
Number of future license agreements under optional purchase right | agreement   2      
Obligation upon exercise of options per licensed product, second agreement   $ 300      
Obligation upon exercise of options per licensed product, third agreement   400      
Payments related to purchase of royalty rights and other commercial payment rights   300      
Long-term royalty and commercial payment receivables   400      
Contingent consideration under RPAs and CPPAs   100      
Changes in estimated fair value of contingent consideration     0    
Payments of contingent consideration     0    
Impairment of long-term royalty receivable     0    
Bioasis | Royalty Purchase Agreement | Maximum          
Agreements          
Potential future cash payments   $ 200      
Bioasis | Second Royalty Purchase Agreement          
Agreements          
Payments related to purchase of royalty rights and other commercial payment rights $ 1,200        
Long-term royalty and commercial payment receivables $ 1,200        
Impairment of long-term royalty receivable     $ 0